Home / Recalls
Consumer Product Recalls
127,277 recalls from the U.S. Consumer Product Safety Commission, newest first.
August 13, 2025DrugsFDA
Cardinal Health Inc. recalls Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55
Hazard: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
August 13, 2025DrugsFDA
Cardinal Health Inc. recalls Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 5
Hazard: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
August 13, 2025DrugsFDA
Direct Rx recalls Duloxetine D/R, 30 mg, 30 Caps, RX Only, Packaged as a) 30-count bottle NDC 61919-0482-30, b) 60-count bottle, NDC 61919
Hazard: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
August 13, 2025DrugsFDA
Direct Rx recalls Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Ph
Hazard: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
August 13, 2025DrugsFDA
Alembic Pharmaceuticals Limited recalls Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Pan
Hazard: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steril
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) su
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile,
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steril
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile,
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile,
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2m
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
AEQUITA PHARMACY recalls Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steril
Hazard: Lack of Processing Controls.
August 13, 2025DrugsFDA
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L.
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
August 13, 2025VehiclesNHTSA
Volkswagen 2025 Steering recall
Hazard: A loss of vehicle control increases the risk of a crash.
August 12, 2025VehiclesNHTSA
Heil 2018–2020 Equipment recall
Hazard: A hydraulic fluid leak in the presence of an ignition source, such as hot engine or exhaust components, can increase the risk of a fire.
August 12, 2025VehiclesNHTSA
Heil 2021–2022 Equipment recall
Hazard: A falling arm increases the risk of injury.
August 12, 2025VehiclesNHTSA
Heil 2024 Fuel System, Other recall
Hazard: An engine stall increases the risk of a crash.
August 12, 2025VehiclesNHTSA
IC BUS 2024–2026 Parking Brake recall
Hazard: A parking brake that is not engaged as expected when the driver releases the brakes may allow the vehicle to rollaway, increasing the risk of crash.
August 12, 2025TiresNHTSA
Dunlop Tires recall
Hazard: Tires that do not provide sufficient traction increase the risk of a crash.
August 11, 2025VehiclesNHTSA
Mack 2025–2026 Steering recall
Hazard: A loss of steering control increases the risk of a crash.
August 11, 2025VehiclesNHTSA
Volvo 2025–2026 Steering recall
Hazard: A loss of steering control increases the risk of a crash.
August 8, 2025VehiclesNHTSA
Ford, Lincoln 2025 Exterior Lighting recall
Hazard: Exterior lighting failure can reduce visibility for the driver and other road users, increasing the risk of a crash.
August 8, 2025VehiclesNHTSA
Lincoln 2024–2025 Visibility recall
Hazard: A closing window may exert excessive force by pinching a driver or passenger before retracting, increasing the risk of injury.
August 8, 2025VehiclesNHTSA
Ford 2022 Exterior Lighting recall
Hazard: Flickering parking lights can reduce visibility, increasing the risk of a crash.